Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma

The HIV-protease inhibitor nelfinavir has shown broad anticancer activity in various preclinical and clinical contexts. In patients with advanced, proteasome inhibitor (PI)–refractory multiple myeloma, nelfinavir-based therapy resulted in 65% partial response or better, suggesting that this may be a...

Descripción completa

Detalles Bibliográficos
Autores principales: Besse, Lenka, Besse, Andrej, Stolze, Sara C., Sobh, Amin, Zaal, Esther A., van der Ham, Alwin J., Ruiz, Mario, Phuyal, Santosh, Büchler, Lorina, Sathianathan, Marc, Florea, Bogdan I., Borén, Jan, Ståhlman, Marcus, Huber, Julia, Bolomsky, Arnold, Ludwig, Heinz, Hannich, J. Thomas, Loguinov, Alex, Everts, Bart, Berkers, Celia R., Pilon, Marc, Farhan, Hesso, Vulpe, Christopher D., Overkleeft, Herman S., Driessen, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Translational Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7611616/
https://www.ncbi.nlm.nih.gov/pubmed/34158378
http://dx.doi.org/10.1158/0008-5472.CAN-20-3323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7611616/
https://www.ncbi.nlm.nih.gov/pubmed/34158378
http://dx.doi.org/10.1158/0008-5472.CAN-20-3323

Ejemplares similares